Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Inclusion Criteria:

1. 55 years of age or older at Screening.

2. Able and willing to give informed consent and attend study visits.

3. Women or intersex individuals must be willing to use 2 forms of effectivecontraception during the study and for at least 90 days following the last dose ofstudy drug, be postmenopausal for at least 12 months prior to study entry, orsurgically sterile. If of childbearing potential, a negative urine pregnancy test isrequired at Screening and prior to the administration of study drug at each visit.

4. Men or intersex individuals with partners of childbearing potential must be willingto use permissible methods of contraception and refrain from sperm donation duringthe study and for at least 90 days following the last dose of study drug.

5. If currently using Age-related Eye Disease Study 2 (AREDS, AREDS2, or similarnutraceutical therapy at Screening, patient must be willing to continue use for theduration of the study. If not currently using AREDS2 or similar, patient must bewilling to continue not to use therapy for the duration of the study. Patient mustagree to choose either approach. Study Eye Inclusion Criteria:

6. BCVA of 24 letters or more using ETDRS charts in the study eye at Screening.

7. Intraocular pressure (IOP) of 22 mmHg or lower in the study eye at Screening. The GA lesion must meet all the following criteria:

8. Non-foveal GA associated with AMD without eMNV in the study eye per Investigator'sevaluation and as confirmed by the central RC.

9. GA ≥0.85 disc area (DA) (2.125 mm2) and ≤8.05 DA (20.125 mm2) in the study eye asconfirmed by the central RC.

10. If GA in the study eye is multifocal, at least 1 focal lesion must be ≥0.425 DA (1.063 mm2) as confirmed by the central RC.

11. Non-foveal GA (GA lesion up to the fovea, but not subfoveal) with the lesion'sclosest border 1725 microns or less from the foveal center in the study eye, asconfirmed by the central RC.

12. The entire GA lesion in the study eye must be completely visualized on themacula-centered FAF image, must be able to be imaged in its entirety, and must notbe contiguous with any areas of peripapillary atrophy per the Investigator'sevaluation and as confirmed by the central RC.

13. A pattern of hyper-autofluorescence in the junctional zone of GA in the study eyemust be present as confirmed by the central RC. Fellow Eye Inclusion Criterion:

14. BCVA of 19 letters or more using ETDRS charts in the fellow eye at Screening.

Exclusion Criteria:

1. Current or planned participation in another investigational clinical study or use ofany other investigational drugs or devices at least 6 months prior to enrollment orduring the study period without prior written Sponsor approval.

2. Previous ophthalmic disease gene therapy or planned participation in any genetherapy clinical study during the study period.

3. Current or planned use of systemic complement inhibitors during the study period.

4. Any ocular or systemic condition that, in the opinion of the Investigator, makes thepatient unsuitable for treatment with an investigational drug or that wouldcompromise the safety or efficacy assessments of the study.

5. Treatment with any ocular or systemic medication that is known to be toxic to thelens, retina, or optic nerve (including, but not limited to, aminoglycosides,vancomycin, hydroxychloroquine, interferon, tacrolimus, cisplatin, bis-chloroethylnitrosourea, carmustine, ethambutol, and tamoxifen) within 90 days prior toScreening or anticipated during the study period.

6. Any previous treatment of pentosan polysulfate (Elmiron®) is exclusionary.

7. Known allergy to fluorescein, povidone iodine, or any ingredients of the study drugor avacincaptad pegol intravitreal solution.

8. Individuals who are currently pregnant, planning to become pregnant, or are nursingat Screening or during the study period. Study Eye Exclusion Criteria:

9. Active ocular or periocular infection in the study eye.

10. Any contraindication to an IVT injection in the study eye.

11. Any media opacity in the study eye that limits visual acuity, clinical visualizationof the retina, or retinal imaging as determined by the Investigator.

12. Previous IVT pharmaceutical treatment in the study eye with any agent except Foodand Drug Administration (FDA)-approved complement inhibitors and treatment withFDA-approved complement inhibitors within 12 weeks prior to Screening.

13. Any history of incisional retinal surgery in the study eye including but not limitedto scleral buckle or vitrectomy. (Retinal laser for a tear or hole 3 months or moreprior to Screening is not exclusionary).

14. History of incisional glaucoma surgery including trabeculectomy, tube shunt, orminimally invasive glaucoma surgery in the study eye. (Glaucoma laser proceduresperformed at least 6 months prior to Screening are not exclusionary).

15. Yttrium aluminum garnet capsulotomy in the study eye within 1 month prior toScreening.

16. Cataract surgery in the study eye planned or expected during the study period.

17. Aphakia with absence of the posterior capsule in the study eye. (Pseudophakia withan open posterior capsule is not exclusionary).

18. Any current evidence or history in the study eye of exudative ("wet") AMD, includingany RPE rips or evidence of actively leaking neovascularization anywhere in theretina based on the FA or SD-OCT as assessed per the Investigator's evaluation andconfirmed by the central RC.

19. Any clinically significant retinal disease other than AMD except benign degenerativeconditions (eg, Cobblestone degeneration) in the study eye.

20. Intraocular surgery in the study eye (including lens replacement surgery) within 3months prior to Screening. See Exclusion Criteria 12 and 13 pertaining to retinaland glaucoma surgery, respectively.

21. Previous therapeutic radiation (including transpupillary thermotherapy, photodynamictherapy, or external-beam) in the region of the study eye. Fellow Eye Exclusion Criterion:

22. Planned or expected IVT injection in the fellow eye for treatment of GA with agentsother than FDA-approved complement inhibitors (pegcetacoplan or avacincaptad pegolIVT solution [Izervay™]) during the study period. Either Eye Exclusion Criteria:

23. Active intraocular inflammation in either eye or a history of uveitis orendophthalmitis in either eye.

24. GA in either eye due to causes other than AMD.

25. Any ophthalmic condition in either eye that is likely to require surgery during thestudy period.